Pointing of Care Testing in Clinical Trials

Stepping back in history, records of bedside Point of Care testing (PoCT) can be traced back as far Ancient Egypt whilst at the same time in India the practice of tasting urine to detect glucose was noted as a primary marker. Thankfully, the investigative techniques used in PoCT have advanced with the passing centuries. Nevertheless, the principals of diagnostic testing performed promptly and conveniently near the patient are as valid now as they were then. In fact, the global Point of Care Testing market is forecast to be worth US$38.13 billion by 2022. The ability to provide immediate diagnostic information reduces the time lost in organising logistics for analysis at a central laboratory (it also helps to minimise workloads here too). In Clinical Trials applications, the results generated prior to administering an investigational medicinal product (IMP) can also act as decision-markers providing key trial data from the outset. PoCT equipment has benefited from the same micro-processing revolution we’ve all experienced through our smartphones. Together with scientific advances such as solid phase chemistry, blood analysers for example have become smaller, more compact and ultimately more portable. With in-house teams of biomedical scientists and medical electronics technicians not only can Woodley source all of your equipment needs; we’re uniquely placed to provide diagnostic recommendations as well as training solutions at every phase of your Study.